Renal Cell Cancer

Phase I/II clinical trial of CpG 7909 initiated

Published in Cancer Weekly, June 4th, 2002

Coley Pharmaceutical Group, Inc., announced that it has initiated a multicenter open label, phase I/II clinical trial of its lead product candidate, CpG 7909, for the treatment of patients with stage IV (metastatic) renal cell carcinoma.

The phase I study will assess the safety and tolerability of escalating doses of CpG 7909. Once these are established, a phase II group of patients will be enrolled to determine overall tumor response and immunologic effects. Other endpoints of the phase II portion of the study include time to disease progression, duration of response and survival time.

"Because our CpG 7909 product candidate stimulates multiple...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-06-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry